Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication.

摘要: There is controversy whether simultaneous thyrostatic medication influences the outcome of radioiodine (131I) therapy in Graves' disease by reducing absorbed energy dose 131I when delivering a standard dose. We therefore sought to ascertain ablative any way affected thyrostasis (carbimazole) aiming for constant 200-250 Gy. prospectively studied 207 patients with (106 and 101 without carbimazole at time therapy). All were reexamined 3, 6, 12 months after therapy. The nonthyrostatic showed highly significantly greater success rate (93%) than 106 (49%). Stepwise logistic regression demonstrated that failure was related administration during (P < 0.00005) 0.025), but not free T3, T4, TSH receptor antibodies, or thyroid volume. 100% 93 doses 200 Gy more, only 12.5% (1 8) less Correlation between higher (r = 0.93 vs. r 0.24). Sixteen who discontinued 1-3 days before 94% successes. Simultaneous decisive factor against successful even if reduced uptake/half-life values under are compensated delivered ensure comparable dose, possibly due additionally effective radioprotective properties carbimazole. Therefore, clinically feasible, we recommend discontinuing least 1 day beginning therapy, because hyperthyroid 100%.